|
|
|
| The self-renewal ability of ganlioside GD2+ breast cancer stem cells via selectively suppressing STAT3 activation |
| ZHU Lihe1, HU Lufeng2, JI Jianle1, ZHU Wei1 |
| 1.Department of Pathology, the Affiliated Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, 325000; 2.Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015. |
|
| Cite this article: |
|
ZHU Lihe,HU Lufeng,JI Jianle, et al. The self-renewal ability of ganlioside GD2+ breast cancer stem cells via selectively suppressing STAT3 activation[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(2): 110-114.
|
|
|
Abstract Objective: To investigate the effect of selectively inhibiting STAT3 on the self-renewal ability of GD2+ breast cancer stem cells by stattic. Methods: The GD2+ breast cancer stem cells were sorted out from human breast cancer cell lines MDA-MB-231 via flow Cytometry. The obtained GD2+ stem cells were identified. Western blot was applied to evaluate the expression of STAT3, pSTAT3 protein. Stattic inhibition test was applied to explore the effect of inhibiting STAT3 on the self-renewal ability of GD2+ breast cancer stem cells. Results: GD2+ breast cancer stem cells grew as spheres cultured in serum-free suspension. The mammpsphere formation number of GD2+ breast cancer stem cells was (22.38±3.44) per 1 000 cells, significantly higher than that of GD2-cells (7.14±1.14) (P<0.05). The ammpsphere size of GD2+ cells was (148.47±41.34) μm, significantly larger than that of GD2- cells (57.10±13.58) μm (P<0.05). Beginning from the second day, GD2+ breast cancer stem cells were less proliferating than GD2- cells (P<0.05). The expression of pSTAT3 protein in GD2+ breast cancer cells was significantly higher than that in GD2- breast cancer cells (P<0.05), but there was no significant difference in the expression of STAT3 protein between the two groups (P>0.05). After the intervention of selective STAT3 inhibitor Stattic on GD2+ breast cancer stem cells, the proliferation and mammpsphere forming ability of breast cancer stem cells were decreased (P<0.05). Conclusion: The selective STAT3 inhibitor Stattic can inhibit the self-renewal ability of GD2+ breast cancer stem cells.
|
|
Received: 12 September 2017
|
| |
|
|
|
[1] AL-EJEH F, SMART C E, MORRISON B J, et al. Breast cancer stem cells: treatment resistance and therapeutic op-portunities[J]. Carcinogenesis, 2011, 32(5): 650-658.
[2] BATTULA V L, SHI Y, EVANS K W, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumor-igenesis[J]. J Clin Invest, 2012, 122(6): 2066-2078.
[3] TELL R W, HORVATH C M. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific tobasal-like breast cancers in human tumors[J]. Proc Natl Acad Sci U S A, 2014, 111(35): 12787-12792
[4] LIN L, HUTZEN B, LEE H F, et al. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells[J]. PloS One, 2013, 8(12): e82821.
[5] ORSI G, BARBOLINI M, FICARRA G, et a1. GD2 expression in breast cancer[J]. Oncotarget, 2017, 8(19): 31592-31600.
[6] 凌人, 凌今, 陈仲华, 等. 14-3-3 zeta蛋白过表达与他莫昔芬治疗乳腺癌耐药的关系[J]. 温州医科大学学报, 2017, 47(3): 192-196.
[7] YEHIELY F, MOYANO J V, EVANS J R, et al. Deconstructing the molecular portrait of basal-like breast cancer[J]. Trends Mol Med, 2006, 12(11): 537-544.
[8] NIELSEN T O, HSU F D, JENSEN K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16): 5367-5374.
[9] MARTINEZ C, HOFMANN T J, MARINO R, et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs[J]. Blood, 2007, 109(10): 4245-4248.
[10] NAVID F, SANTANA V M, BARFIELD R C. Anti-GD2 antibody therapy for GD2-expressing tumors[J]. Curr Cancer Drug Targets, 2010, 10(2): 200-209.
[11] KOHLA G, STOCKFLETH E, SCHAUER R. Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin[J]. Neurochem Res, 2002, 27(7-8): 583-592.
[12] THURIN J, THURIN M, HERLYN M, et al. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression[J]. FEBS Lett, 1986, 208(1): 17-22.
[13] KAILAYANGIRI S, ALTVATER B, MELTZER J, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune target-ing[J]. Br J Cancer, 2012, 106(6): 1123-1133.
[14] LONG A H, HIGHFILL S L, CUI Y, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas[J]. Cancer Immunol Res, 2016, 4(10): 869-880.
[15] AL-HAJJ M, WICHA M S, BENITO-HERNANDEZ A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci U S A, 2003, 100(7): 3983-3988.
[16] GINESTIER C, HUR M H, CHARAFE-JAUFFRET E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J].Cell Stem Cell, 2007, 1(5): 555-567.
[17] LEVY D E, DARNELL J E JR. Stats: transcriptional control and biological impact[J]. Nat Rev Mol Cell Biol, 2002, 3(9): 651-662.
[18] CLEVENGER C V. Roles and regulation of stat family transcription factors in human breast cancer[J]. Am J Pathol, 2004, 165(5): 1449-1460.
|
|
|
|
